Trade PURETECH HEALTH PLC ORD 1P - PRTC CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.00436
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment£1,000.00Overnight funding adjustmentCharges from full value of position-0.02128 %(-£1.06)Trade size with leverage ~ £5,000.00Money from leverage ~£4,000.00Go to platform: -0.02128%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment£1,000.00Overnight funding adjustmentCharges from full value of position-0.00064 %(-£0.03)Trade size with leverage ~ £5,000.00Money from leverage ~£4,000.00Go to platform: -0.00064%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: GBP
• Min traded quantity: 10
• Margin: 20.00%
• Stock exchange: Great Britain
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: £1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02128 %
  (-£1.06)

• Margin. Your investment: £1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00064 %
  (-£0.03)

Key Stats

• Prev. Close: 1.16683
• Open: 1.14882
• 1-Year Change: -13.13%
• Day's Range: 1.14882 - 1.17682

Trade PURETECH HEALTH PLC ORD 1P - PRTC

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders; microbiome-derived immune modulators for maternal and paediatric health; novel approach to oral delivery of biologics, vaccines, and other drugs; platform to address androgenetic alopecia; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist programme for the treatment of psychosis and cognition, including schizophrenia and Alzheimer''s; monoclonal antibody-based therapeutic to treat pancreatic cancer and other solid tumors; voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, such as depression, Alzheimer''s disease, multiple sclerosis, and Parkinson''s disease; platform and products that seek to explore and leverage the health potential of music; therapies for immune-mediated and infectious diseases based on rationally-defined consortium of human microbiome-derived bacteria; and novel antibody and cell therapies for treating cancer. It is also developing a milk exosome-based technology designed to enable the oral administration of biologics, nucleic acids, and complex small molecules; and a lipid prodrug technology to enable lymphatic targeting. In addition, the company''s medical device programme is developing a non-invasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder. PureTech Health plc was incorporated in 2015 and is headquartered in Boston, Massachusetts.